Phosphoenolpyruvate was found to be transported across the erythrocyte membrane by a carrier-mediated transport system. The transport of phosphoenolpyruvate was competitively inhibited by inorganic phosphate (Ki = 24 mM) and pyridoxal 5-phosphate (Ki = 0.2 mM), whereas the transport was noncompetitively inhibited by L(+)-lactate (Ki = 37 mM). Specific inhibitors for the inorganic anion transport system such as 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid and 4,4'-dinitrostilbene-2,2'-disulfonic acid strongly inhibited the phosphoenolpyruvate transport. The transport was irreversibly inhibited by treating erythrocytes with pyridoxal 5-phosphate and NaBH4. Transport activities of phosphoenolpyruvate and inorganic phosphate in the treated cells were similarly inhibited by pyridoxal 5-phosphate depending on its concentrations. 4,4'-Dinitrostilbene-2,2'-disulfonic acid protected both transport activities against the pyridoxal 5-phosphate/NaBH4 treatment. The major integral membrane protein, band 3, was preferentially labelled by treating erythrocytes with pyridoxal 5-phosphate and NaB[3H]H4. The radioactive incorporation into band 3 was confirmed by two-dimensional gel electrophoresis combining isoelectric focusing in the first dimension and sodium dodecyl sulfate/polyacrylamide gel electrophoresis in the second dimension. Taken together, these results suggest that band 3 mediates the transport of phosphoenolpyruvate as well as inorganic phosphate.
No takes yet. Share an insight, caveat, or question.
Hamasaki et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: